Author

Kevin D. Burroughs

Observed names: Burroughs, K.D., K Burroughs, K. Burroughs, K. D. Burroughs, KD Burroughs, Kevin Burroughs, Kevin D Burroughs

Observed institutions: National Institutes of Health, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Princeton University, Johns Hopkins Medicine, Mary Crowley Cancer Research Center, National Institute of Environmental Health Sciences, Novartis (United States), Sidney Kimmel Comprehensive Cancer Center, Wyeth

OpenAlex ID: A5035524529

Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus, and the Treatment of Neuroendocrine Cancers

2007 · P. Seshidhar Reddy, Kevin D. Burroughs, et al. · JNCI Journal of the National Cancer Institute · 242

Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

2011 · Charles M. Rudin, John T. Poirier, et al. · Clinical Cancer Research · 153

PDF

Structural Features of the Seneca Valley Virus Internal Ribosome Entry Site (IRES) Element: a Picornavirus with a Pestivirus-Like IRES

2011 · Margaret M. Willcocks, Nicolas Locker, et al. · Journal of Virology · 86

Altered Hormonal Responsiveness of Proliferation and Apoptosis During Myometrial Maturation and the Development of Uterine Leiomyomas in the Rat1

2000 · Kevin D. Burroughs, Robin Fuchs-Young, et al. · Biology of Reproduction · 77

Preclinical Evidence for Therapeutic Efficacy of Selective Estrogen receptor Modulators for Uterine Leiomyoma

2000 · Cheryl Lyn Walker, Kevin D. Burroughs, et al. · Journal of the Society for Gynecologic Investigation · 71

Insulin-Like Growth Factor-I: a Key Regulator of Human Cancer Risk?

1999 · K. D. Burroughs, S. E. Dunn, et al. · JNCI Journal of the National Cancer Institute · 71

PDF

Serotonin 2A receptors modulate tail-skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction

2004 · Kimberly Sipe, Liza Leventhal, et al. · Brain Research · 60

Dysregulation of IGF-I signaling in uterine leiomyoma

2002 · KD Burroughs, SR Howe, et al. · Journal of Endocrinology · 58

PDF

Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1?

2003 · Kevin D Burroughs, Jennifer Oh, et al. · PubMed · 50

Regulation of Apoptosis in Uterine Leiomyomata1

1997 · Kevin D. Burroughs, Kaoru Kiguchi, et al. · Endocrinology · 33

Efficacy of LGD1069 (Targretin), a Retinoid X Receptor-Selective Ligand, for Treatment of Uterine Leiomyoma

2000 · Shantini D. Gamage, Eric D. Bischoff, et al. · Journal of Pharmacology and Experimental Therapeutics · 29

Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001

2012 · John T. Poirier, P. Seshidhar Reddy, et al. · Journal of General Virology · 28

Structure−Activity Relationships of the Cycloalkanol Ethylamine Scaffold: Discovery of Selective Norepinephrine Reuptake Inhibitors

2008 · Paige E. Mahaney, Lori K. Gavrin, et al. · Journal of Medicinal Chemistry · 24

Structure–activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors

2009 · Paige E. Mahaney, Callain Y. Kim, et al. · Bioorganic & Medicinal Chemistry Letters · 14

Regulation of Apoptosis in Uterine Leiomyomata

1997 · K. D. Burroughs · Endocrinology · 13

PDF

Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL

2004 · Kevin D Burroughs, Dawn B Kayda, et al. · Cancer Gene Therapy · 9

Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors

2010 · Joseph P. Sabatucci, Paige E. Mahaney, et al. · Bioorganic & Medicinal Chemistry Letters · 8

Phase I study of intravenous Seneca Valley virus (NTX-010), a replication competent oncolytic virus, in patients with neuroendocrine (NE) cancers

2009 · C. M. Rudin, N. Senzer, et al. · Journal of Clinical Oncology · 8

A randomized double-blind phase II study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: Alliance (NCCTG) N0923 study.

2013 · Julian R. Molina, Sumithra J. Mandrekar, et al. · Journal of Clinical Oncology · 7

Discovery of WAY-260022, a Potent and Selective Inhibitor of the Norepinephrine Transporter

2010 · Lori K. Gavrin, Paige E. Mahaney, et al. · ACS Medicinal Chemistry Letters · 3

Phase I trial of Seneca Valley Virus (NTX-010), a newly discovered systemically deliverable oncolytic picornavirus, in patients with solid tumors with neuroendocrine features

2007 · C. M. Rudin, D. Lansey, et al. · Journal of Clinical Oncology · 1

291. In Vivo Characterization of Seneca Valley Virus (SVV-001), a Novel Oncolytic Picornavirus for Systemic Treatment of Patients with Solid Tumors with Neuroendocrine Features

2006 · Kevin D. Burroughs, Kristine Skele, et al. · Molecular Therapy · 1

Data from Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

2023 · Charles M. Rudin, John T. Poirier, et al.

Data from Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

2023 · Charles M. Rudin, John T. Poirier, et al.

Supplementary Figure S1 from Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

2023 · Charles M. Rudin, John T. Poirier, et al.

Works count: 30

Citation count: 1,049

H-index: 14

I10-index: 15